UNITE4TB Webinar: Unprecedented Progress in Shortening Treatment for TB: Evidence to date and Future Possibilities


07 July 2022



This 1-hour webinar will be chaired by Raquel Duarte & Christoph Lange, with Patrick Phillips as a speaker. It will take place on the 7th of July (13:00 – 14:00 CET).

Registration is free through the link below and open to all.

For non-members of the European Respiratory Society (ERS), all that is needed is to create a myERS profile, which can be done for free and in just a few minutes, in order to then register for the webinar.




The last two years have seen unprecedented progress in shortening the treatment for both drug-sensitive and drug-resistant tuberculosis. We have seen the treatment for rifampicin-sensitive TB cut from 6 to 4 months for both adults and children with minimal disease. Furthermore, the treatment for many forms of drug-resistant disease reduced first from 18 to 9, and now to 6 months. However, there are still many unanswered questions that have not been adequately addressed, and weak evidence to support them.

UNITE4TB aims to set a new standard for anti-TB regimen development, by upgrading current clinical trial methodology and enhancing the efficiency with which new regimes are delivered. “Unprecedented Progress in Shortening Treatment for TB: Evidence to date and Future Possibilities” is the third webinar of a series from the UNITE4TB project, where the speaker – Prof. Patrick Phillips of the University of California, will provide an overview on the progress of shorter treatment regimes for TB, whilst providing space for reflection on the current evidence gap on clinical trials, as well as the future possibilities in this field. This Panel Discussion will be divided into 2 parts: first the presentation by the speaker; followed by a discussion moderated by Prof. Dr. Raquel Duarte and Prof. Dr. Cristoph Lange.